SS
ZBIO

Sunbelt Securities’s Zenas BioPharma ZBIO Stock Holding History

Sunbelt Securities’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$215 Hold
11
– – ﹤0.01% 2495
2025
Q4 		$399 Hold
11
– – ﹤0.01% 2277
2025
Q3 		$244 Buy
+11
New +$179 ﹤0.01% 2381

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NA
NVP Associates Menlo Park, California $176M AUM 208.78% 1-Year Est. Return

Sunbelt Securities's ZBIO Position: Q1 2026 in Review

Sunbelt Securities held its Zenas BioPharma (ZBIO) position steady in Q1 2026 at 11 shares worth $215. The position accounts for ﹤0.01% of the portfolio, ranked #2495.

Sunbelt Securities first reported a position in ZBIO in Q3 2025 and has held it in 3 quarters since. The position peaked at $399 in Q4 2025. 139 funds tracked by Wall St. Rank hold ZBIO as of Q1 2026.

  • Sunbelt Securities held 11 shares of Zenas BioPharma worth $215 as of Q1 2026.
  • Sunbelt Securities left its Zenas BioPharma share count unchanged in Q1 2026.
  • Zenas BioPharma made up ﹤0.01% of Sunbelt Securities's portfolio in Q1 2026, its #2495 holding.
  • Sunbelt Securities first reported a position in Zenas BioPharma in Q3 2025 and has held it in 3 quarters since.
  • Sunbelt Securities's Zenas BioPharma position peaked at $399 in Q4 2025.
  • 139 funds tracked by Wall St. Rank held Zenas BioPharma as of Q1 2026.

Based on Sunbelt Securities's 13F filing for Q1 2026, filed 18 May 2026.